DG-Chrom AT L

DG-Chrom AT L

Product Detail Specification
Testing Antithrombin activity
Methodology Chromogenic (liquid)
Components
  • 1 vial of 20 mL (0.7 fl oz) DG-FXa L, liquid bovine Factor Xa solution (approximately 2 nkat/mL)
  • 1 vial of 8 mL (0.3 fl oz) DG-FXa Sust L, liquid chromogenic substrate solution specific for Fxa
Intended use For use to determine the functional Antithrombin (AT) in human plasma
DG-Chrom Hep

DG-Chrom Hep

Product Detail Specification
Testing Heparin concentration: UHF and LMWH
Methodology Chromogenic
Components
  • 2 x 20 mL (0.068 x 0.71 fl oz) DG-Reagent Dil: Tris buffer, pH 8.4
  • 1 vial of DG-FXa: lyophilized bovine FXa (approx. 40 nkat). To be reconstituted with 20 mL of DG-Hep Dil
  • 1 vial of DG-AT: lyophilized human AT (20 IU). To be reconstituted with 20 mL (0.68 fl oz) of DG-Hep Dil
  • 1 vial of DG-Fxa Sust: powdered chromogenic substrate. To be reconstituted with 8 mL of purified water
Intended use To use to determine quantitatively functional unfractioned (UFH) and low molecular weight (LMWH) heparin in human plasma
DG-Chrom PC

DG-Chrom PC

Product Detail Specification
Testing Protein C activity
Methodology Chromogenic
Components
  • 2 x 3 mL (2 x 0.1 fl oz) DG-PC Act, lyophilized, snake-venom as an activator a specific fraction of the venom of Agkistrodon Contortrix
  • 2 x 3 mL (2 x 0.1 fl oz) DG-aPC Subst, lyophilized aPC specific substrate por APC
  • 1 vial of 7 mL (0.2 fl oz) of DG-PC Act Dil: diluent for DG-PC Act
  • 1 vial of 7 mL (0.2 fl oz) of DG-APC Sust Dil: diluent for DG-APC Sust
Intended use For use in the in vitro quantitative determination of direct Factor Xa inhibitors in citrated human plasma
DG-Chrom Anti-Xa

DG-Chrom Anti-Xa

Product Detail Specification
Testing Rivaroxaban concentration
Methodology Clotting
Components
  • 1 vial of DG-Sample Dil
  • 1 vial of DG-Reagent Dil
  • 1 vial of DG-FXa Liof
  • 1 vial of DG-FXa Sust
Intended use For use in the in vitro quantitative determination of direct Factor Xa inhibitors in citrated human plasma
DG-APC

DG-APC

Product Detail Specification
Testing APC resistance factor V
Leiden
Methodology Clotting
Components
  • 3 x 2 mL (0.07 fl oz) DG-RVV/APC. Contains APC, RVV-V, Polybrene, Hepes, and BSA
  • 3 x 2 mL (0.07 fl oz) DG-RVV. Contains RVV-V, Polybrene, Hepes, and BSA
  • 3 x 4 mL (0.14 fl oz) DG-PTA. Prothrombin 3 x 4 ml DG-PTA. Prothrombin
  • 3 x 2 mL (0.07 fl oz) DG-Dil. Dilution plasma, human
  • 1 x 1 mL (0.03 fl oz) DG-APC POS. Positive control, lyophilized human plasma
  • 1 x 1 mL (0.03 fl oz) DG-APC NEG. Negative control, lyophilized human plasma
Intended use For the determination of resistance to activated protein C (APC) caused by the factor V Leiden mutation (FV: Q506)
DG-Clot PS

DG-Clot PS

Product Detail Specification
Testing Protein S activity screening
Methodology Clotting
Components
  • 4 x 1 mL (0.03 fl oz) DG-PS Def, lyophilized, human plasma depleted of Protein S by immunoadsorption
  • 4 x 1 mL (0.03 fl oz) DG-PS Act, lyophilized, human activated Protein C, bovine Fxa and rabbit brain phospholipids
  • 1 x 2.5 mL (0.09 fl oz) DG-PS Buffer, 10x concentrated buffer (0.2 M NaCl, 0.03 M HEPES and an antiheparin agent)
  • 1 x 10 mL (0.34 fl oz) DG-CaCl2 0.025 M, calcium chloride 0.025 M
Intended use For use in the quantitative determination of free Protein S activity in human plasma, by measuring the degree of prolongation of the clotting time
DG-DRVVT

DG-DRVVT

Product Detail Specification
Testing Lupus anticoagulant screening
Methodology Clotting
Components 5 x 2 mL DG-DRVVT is a simplified lyophilized reagent: RVV, phospholipids, antiheparin agents, calcium, stabilizing buffers, sodium azide and colorants
Intended use For use in the determination of Lupus Anticoagulants (LA) in human plasma in one-step coagulation test (screening test)
DG-DRVVT Confirm

DG-DRVVT Confirm

Product Detail Specification
Testing Lupus anticoagulant confirmatory
Methodology Clotting
Components 5 x 1 mL (0.03 fl oz) DG-DRVVT Confirm is a phospholipid-rich lyophilized reagent: RVV, phospholipids, antiheparin agents, calcium, stabilizing buffers, sodium azide sodium azide, and colorants
Intended use To confirm the presence of LAs in human plasma that resulted positive for DG-DRVVT test
DG-Clot DTI

DG-Clot DTI

Product Detail Specification
Testing Dabigatran concentration
Methodology Clotting
Components
  • 1 vial of DGF-Sample Dil with 25 mL (0.85 fl oz) of buffer (pH 7.4) with a heparin inhibitor and preservative (0.0015% isothiazolones)
  • 2 x DG-TT L Human with 3 mL (0.1 fl oz) of buffer (pH 8.4). It contains human thrombin (approx. 2 IU/mL) in a buffered solution with calcium chloride, stabilizers and preservative (0.0015% isothiazolinones)
  • 3 x DG-PNP with 1 mL (0.03 fl oz) of citrated human pooled-plasma from healthy donors containing stabilizers (it does not contain preservatives)
Intended use For the quantitative determination of direct thrombin inhibitors

This information is intended for physicians and healthcare professionals only.

Product registration and availability vary by country. For more information on product availability, please contact us here.